Sign in

    AstraZeneca PLC (AZN)

    Q2 2024 Earnings Summary

    Reported on Feb 18, 2025 (Before Market Open)
    Pre-Earnings Price$79.71Last close (Jul 24, 2024)
    Post-Earnings Price$76.64Open (Jul 25, 2024)
    Price Change
    $-3.07(-3.85%)

    What went well

    • Strong confidence in oncology pipeline with multiple upcoming catalysts: AstraZeneca executives expressed optimism about upcoming trial results, particularly for Imfinzi in bladder cancer, which they expect to be a "blockbuster plus opportunity." They are also confident in the potential of Dato-DXd (Dato), highlighting its best-in-class profile and broad clinical development plan across various cancer types.
    • Expansion into the obesity and weight management market with a comprehensive plan: The company is confident in its GLP-1 assets and has a strategic plan targeting different segments of the obesity market, including weight management for patients with lower BMI and obesity treatments requiring titration and combination therapies. This presents significant future growth potential.
    • Strategic acquisitions and accelerated clinical trials enhancing future growth prospects: AstraZeneca's acquisition of Amolyt Pharma adds eneboparatide, currently in Phase III for hypoparathyroidism—a potential blockbuster opportunity—to their rare disease portfolio. Additionally, the company is accelerating clinical trials, aiming for earlier launches and strengthening its pipeline.

    What went wrong

    • Uncertainty around the future growth of key products Symbicort and Farxiga due to potential volume-based procurement in China and pricing dynamics in the US.
    • Potential delays or reductions in collaboration revenue, as the company assumes flat collaboration revenue for the year, which may impact overall earnings growth.
    • Regulatory risks associated with key pipeline drugs like Dato-DXd and Truqap, including uncertainty about FDA approval timelines and challenges in clinical trial results, which may affect future revenue growth.

    Q&A Summary

    1. Impact of IRA on Pipeline
      Q: Has IRA affected your development decisions?
      A: Pascal Soriot explained that the IRA challenges small molecules, leading them to shift towards biologics like bispecifics, cell therapy, ADCs, and radioconjugates. They may delay U.S. filings for small indications to avoid starting the IRA "clock" prematurely.

    2. Uncertainties in Guidance
      Q: Can you discuss uncertainties around Symbicort and Farxiga?
      A: The company expects continued strength in core strategic products, but uncertainties exist for Symbicort and Farxiga. For Farxiga, particularly in China due to the timing of the VBP process, and for Symbicort in the U.S. regarding the durability of current trends.

    3. Collaboration Revenue Guidance
      Q: Why isn't collaboration revenue expected to increase?
      A: Collaboration revenues are uncertain due to unpredictable timing of partnerships. They assume stable collaboration revenue in guidance, reflecting best estimates.

    4. Obesity Strategy
      Q: What's your strategy in obesity?
      A: AstraZeneca is exploring both incretin and non-incretin pathways, with a plan for weight management and obesity segments. They have an orally bioavailable GLP-1 agonist, AZD5004, moving into Phase IIb, and are confident in their GLP-1 assets.

    5. Enhertu Growth Outlook
      Q: Why isn't Enhertu's growth stronger?
      A: Enhertu is in early stages; growth was impacted by destocking in China. They expect more robust sequential growth in the second half, with upcoming catalysts in breast cancer and tumor-agnostic approvals.

    6. Dato-DXd Pipeline Updates
      Q: Can you update on Dato-DXd progress?
      A: Dato-DXd filings remain under review; discussions with FDA are ongoing. They are optimistic about upcoming data in lung and breast cancer, confident in its best-in-class potential.

    7. Medicare Part D Impact
      Q: What's the impact of Medicare Part D reform?
      A: Contracting for 2025 is ongoing; differentiation remains key. They see improvements in patient affordability and manageable headwinds due to IRA.

    8. Farxiga Under VBP
      Q: When will Farxiga face VBP in China?
      A: Farxiga may enter VBP late this year, with potential price cuts less than 30%.

    9. Margins in Emerging Markets
      Q: How are margins in emerging markets?
      A: Operating margins are viable, closer to European levels, supporting continued investment. Emerging markets drive growth and profit.

    10. Legacy Products Growth
      Q: Is growth in legacy products sustainable?
      A: Older products are expected to continue growing, especially in emerging markets where there's strong brand loyalty. Uncertainties exist but may resolve positively.

    Related Publications